Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Anastasia L. Khandazhinskaya is active.

Publication


Featured researches published by Anastasia L. Khandazhinskaya.


Bioorganic & Medicinal Chemistry | 2013

N1,N3-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase.

Mikhail S. Novikov; Vladimir T. Valuev-Elliston; Denis A. Babkov; Maria P. Paramonova; A. V. Ivanov; Sergey A Gavryushov; Anastasia L. Khandazhinskaya; S. N. Kochetkov; Christophe Pannecouque; Graciela Andrei; Robert Snoeck; Jan Balzarini; Katherine L. Seley-Radtke

Abstract A series of phenyloxyethyl and cinnamyl derivatives of substituted uracils were synthesized and found to exhibit potent activity against HIV-RT and HIV replication in cell culture. In general, the cinnamyl derivatives proved superior to the phenyloxyethyl derivatives, however 1-[2-(4-methylphenoxy)ethyl]-3-(3,5-dimethylbenzyl)uracil (19) exhibited the highest activity (EC50 =0.27μM) thus confirming that the 3-benzyluracil fragment in the NNRTI structure can be regarded as a functional analogue of the benzophenone pharmacophore typically found in NNRTIs.


Drug Metabolism and Disposition | 2009

5′-Aminocarbonyl Phosphonates as New Zidovudine Depot Forms: Antiviral Properties, Intracellular Transformations, and Pharmacokinetic Parameters

Anastasia L. Khandazhinskaya; Dmitry V. Yanvarev; Maxim V. Jasko; Alexander V. Shipitsin; Vsevolod A. Khalizev; Stanislav I. Shram; Yuriy S. Skoblov; Elena A. Shirokova; Marina K. Kukhanova

The main disadvantages of 3′-azido-3′-deoxythymidine (zidovudine, AZT), the most common anti-HIV drug, are toxicity and a short half-life in the organism. The introduction of an H-phosphonate group into the AZT 5′ position resulted in significant improvement of its therapeutic properties and allowed a new anti-HIV drug, Nikavir (AZT H-phosphonate). In this work, we described a new group of AZT derivatives, namely, AZT 5′-aminocarbonylphosphonates. The synthesized compounds displayed antiviral properties in cell cultures infected with HIV-1 and the capacity to release the active nucleoside in animals (rabbits and dogs) in a dose-dependent manner. The compounds were less toxic in MT-4 and HL-60 cell cultures and experimental animals compared with AZT. Major metabolites found in MT-4 cells after their incubation with AZT 5′-aminocarbonylphosphonate 1 were AZT and AZT 5′-phosphate (25 and 55%, respectively). Among the tested compounds, phosphonate 1 was the most effective AZT donor, and its longest t1/2 and Tmax values in the line phosphonate 1 - AZT H-phosphonate - AZT imply that compound 1 is an extended depot form of AZT. Although bioavailability of AZT after oral administration of phosphonate 1 was lower than those of AZT H-phosphonate and AZT (8 against 14 and 49%), we expect that this reduction would not cause essential decrease of antiviral activity but noticeably decrease toxicity as a result of gradual accumulation of AZT in blood and the absence of sharp difference between Cmax and Cmin. Such a combination of properties makes the compounds of this group promising for further studies as extended-release forms of AZT.


Bioorganic & Medicinal Chemistry | 2010

1-Benzyl derivatives of 5-(arylamino)uracils as anti-HIV-1 and anti-EBV agents

Mikhail S. Novikov; Robert W. Buckheit; Kartik Temburnikar; Anastasia L. Khandazhinskaya; A. V. Ivanov; Katherine L. Seley-Radtke

Pyrimidine analogs have long found use over a broad chemotherapeutic spectrum. In an effort to further explore the antiviral potential of several uracil derivatives previously synthesized in our laboratories, a series of benzylated pyrimidines were designed and synthesized. Introduction of the benzyl residue onto the 5-phenylaminouracil scaffold was carried out using 2,4-bis(trimethylsilyloxy)pyrimidine with the corresponding benzyl bromides. Similarly, 1-benzyl-5-(benzylamino)- and 1-benzyl-5-(phenethylamino)uracils were obtained via amination of 1-benzyl-5-bromouracils with benzylamine or phenylethylamine. The results of the broad screen antiviral studies revealed that compounds 5 and 11 exhibit promising inhibitory activity against HIV-1 in CEM-SS culture. A 50% protective effect was observed at concentrations of 11.9 and 9.5 μМ, respectively. Moreover, compounds 8 and 3 exhibited good inhibitory effects against EBV in АKАТА cell culture with EC₅₀ values of 2.3 and 12 μM, respectively. The synthesis and biological studies are detailed herein.


Bioorganic Chemistry | 2010

1,2,4-Triazoloazine derivatives as a new type of herpes simplex virus inhibitors

S.L. Deev; M.V. Yasko; Inna L. Karpenko; A.N. Korovina; Anastasia L. Khandazhinskaya; V.L. Andronova; G.A. Galegov; T.S. Shestakova; E.N. Ulomskii; Vladimir L. Rusinov; O. N. Chupakhin; Marina K. Kukhanova

A new class of inhibitors of herpes simplex virus replication was found. The compounds under study are derived from condensed 1,2,4-triazolo[5,1-c][1,2,4]triazines and 1,2,4-triazolo[1,5-a]pyrimidines, structural analogues of natural nucleic bases. Antiherpetic activity and cytotoxicity of the compounds were studied. The corresponding triphosphates of several active compounds were prepared and tested as inhibitors of DNA synthesis catalyzed by herpes simplex virus polymerase. The potential mechanism of their action is blocking of DNA dependent DNA polymerase, a key enzyme of viral replication.


Bioorganic & Medicinal Chemistry | 2013

Synthesis and anti-HCMV activity of 1-[ω-(phenoxy)alkyl]uracil derivatives and analogues thereof

Mikhail S. Novikov; Denis A. Babkov; Maria P. Paramonova; Anastasia L. Khandazhinskaya; Alexander Ozerov; Alexander O. Chizhov; Graciela Andrei; Robert Snoeck; Jan Balzarini; Katherine L. Seley-Radtke

Abstract HCMV infection represents a life-threatening condition for immunocompromised patients and newborn infants and novel anti-HCMV agents are clearly needed. In this regard, a series of 1-[ω-(phenoxy)alkyl]uracil derivatives were synthesized and examined for antiviral properties. Compounds 17, 20, 24 and 28 were found to exhibit highly specific and promising inhibitory activity against HCMV replication in HEL cell cultures with EC50 values within 5.5–12μM range. Further studies should be undertaken to elucidate the mechanism of action of these compounds and the structure–activity relationship for the linker region.


MedChemComm | 2013

Structure-activity evaluation of new uracil-based non-nucleoside inhibitors of HIV reverse transcriptase

Elena S. Matyugina; Vladimir T. Valuev-Elliston; Alexander N. Geisman; Mikhail S. Novikov; Alexander O. Chizhov; S. N. Kochetkov; Katherine L. Seley-Radtke; Anastasia L. Khandazhinskaya

A new series of potential nonnucleoside inhibitors of HIV-1 reverse transcriptase (NNRTIs) based on the carbocyclic 5′-nor-uracil scaffold were designed and synthesized. Three different aspects of the scaffold were investigated: the effects of adding a linker between the carbocyclic and phenyl fragments, introduction of different substituents on the benzoyl residue and replacing the central carbocyclic ring with a benzyl group. Analogues of 2′,3′-dideoxy-2′,3′-didehydro-5′-nor-uridine, bearing 3,5-dichloro- or 3,5-dimethylbenzoyl groups, showed inhibitory activity against HIV-RT wild-type (IC50 5–10 μM) and mutants L100I (IC50 1.2–2.1 μM) and K103N (IC50 8–17 μM).


Antiviral Research | 2014

A new antiviral: Chimeric 3TC–AZT phosphonate efficiently inhibits HIV-1 in human tissues ex vivo

Christophe Vanpouille; Anastasia L. Khandazhinskaya; Inna L. Karpenko; Sonia Zicari; Victor Barreto-de-Souza; Svetlana Frolova; Leonid Margolis; S. N. Kochetkov

Although more-recently developed antivirals target different molecules in the HIV-1 replication cycle, nucleoside reverse transcriptase inhibitors (NRTIs) remain central for HIV-1 therapy. Here, we test the anti-HIV activity of a phosphonate chimera of two well-known NRTIs, namely AZT and 3TC. We show that this newly synthesized compound suppressed HIV-1 infection in lymphoid tissue ex vivo more efficiently than did other phosphonates of NRTIs. Moreover, the new compound was not toxic for tissue cells, thus making the chimeric phosphonate strategy a valid approach for the development of anti HIV-1 compound heterodimers.


Tetrahedron Letters | 2013

A highly facile approach to the synthesis of novel 2-(3-benzyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-N-phenylacetamides

Mikhail S. Novikov; Denis A. Babkov; Maria P. Paramonova; Alexander O. Chizhov; Anastasia L. Khandazhinskaya; Katherine L. Seley-Radtke

Abstract A series of heterocyclic compounds were designed as potential nonnucleoside HIV reverse transcriptase inhibitors. Although the compounds ultimately proved inactive against HIV, during the course of the synthesis, a new and highly facile method to realize N-phenylacetamides was developed. Notably, the new route avoids the intractable workups and byproducts previously reported procedures have been associated with, thereby making this approach highly attractive to adaptation with other heterocyclics.


MedChemComm | 2013

5′-Nor carbocyclic nucleosides: unusual nonnucleoside inhibitors of HIV-1 reverse transcriptase

Elena S. Matyugina; Vladimir T. Valuev-Elliston; Denis A. Babkov; Mikhail S. Novikov; A. V. Ivanov; S. N. Kochetkov; Jan Balzarini; Katherine L. Seley-Radtke; Anastasia L. Khandazhinskaya

A new series of potential nonnucleoside inhibitors of HIV-1 reverse transcriptase (NNRTIs) based on the carbocyclic 5′-nor-uracil scaffold were designed and synthesized. Binding modes in the active site of the enzyme were studied computationally to provide insight on potential interactions. Several of the 2′,3′-dideoxy-2′,3′-didehydro-5′-nor-uridine analogues showed inhibitory activity against wild-type and mutant (L100I) HIV-RT with Ki 13–18 μM and 1–11 μM, respectively.


Bioorganic & Medicinal Chemistry | 2015

Scaffold hopping: Exploration of acetanilide-containing uracil analogues as potential NNRTIs

Denis A. Babkov; Vladimir T. Valuev-Elliston; Maria P. Paramonova; Alexander Ozerov; A. V. Ivanov; Alexander O. Chizhov; Anastasia L. Khandazhinskaya; S. N. Kochetkov; Jan Balzarini; Dirk Daelemans; Christophe Pannecouque; Katherine L. Seley-Radtke; Mikhail S. Novikov

In order to identify novel nonnucleoside inhibitors of HIV-1 reverse transcriptase two series of amide-containing uracil derivatives were designed as hybrids of two scaffolds of previously reported inhibitors. Subsequent biological evaluation confirmed acetamide uracil derivatives 15a-k as selective micromolar NNRTIs with a first generation-like resistance profile. Molecular modeling of the most active compounds 15c and 15i was employed to provide insight on their inhibitory properties and direct future design efforts.

Collaboration


Dive into the Anastasia L. Khandazhinskaya's collaboration.

Top Co-Authors

Avatar

Elena S. Matyugina

Engelhardt Institute of Molecular Biology

View shared research outputs
Top Co-Authors

Avatar

S. N. Kochetkov

Engelhardt Institute of Molecular Biology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Vladimir T. Valuev-Elliston

Engelhardt Institute of Molecular Biology

View shared research outputs
Top Co-Authors

Avatar

Inna L. Karpenko

Engelhardt Institute of Molecular Biology

View shared research outputs
Top Co-Authors

Avatar

Marina K. Kukhanova

Engelhardt Institute of Molecular Biology

View shared research outputs
Top Co-Authors

Avatar

A. V. Ivanov

Russian Academy of Sciences

View shared research outputs
Top Co-Authors

Avatar

Kochetkov Sn

Engelhardt Institute of Molecular Biology

View shared research outputs
Top Co-Authors

Avatar

Maxim V. Jasko

Engelhardt Institute of Molecular Biology

View shared research outputs
Researchain Logo
Decentralizing Knowledge